Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

Inclusion Criteria: * Has a diagnosis of HCC confirmed by radiology, histology, or cytology * Has HCC localized to the liver and not amenable to curative treatment * Participants with Hepatitis C virus (HCV) are eligible if treatment was completed at least 1 month prior to starting study intervention * Participants with Hepatitis B virus (HBV) are eligible * Has adequately controlled blood pressure with or without antihypertensive medications * Has adequate organ function Exclusion Criteria: * Is currently a candidate for liver transplantation * Has had gastric bleeding within the last 6 months * Has ascites that is not controlled with medication * Has significant cardiovascular impairment within 12 months of the first dose of study intervention such as congestive heart failure * Has a serious nonhealing wound, ulcer, or bone fracture * Has received locoregional therapy to existing liver lesions